Login or sign up
For business

Retrotope inc.

3.9Β· 11 reviews
Average ratingAverage
3.9/ 5

Based on 11 reviews

527%
436%
336%
20%
10%
Ask AI

Questions about Retrotope inc.

Based on 11 reviews, listing data and website checks Β· updated 8 days ago

What is Retrotope inc.?

Retrotope inc. is a pharmaceutical company based in Los Altos, California, developing proprietary therapeutics to treat degenerative diseases by down-regulating lipid peroxidation (LPO). Their pipeline includes first-in-class candidates like RT001 and RT011 targeting conditions such as ALS, INAD, Friedreich's ataxia, and Dry AMD. The company leverages a proprietary drug discovery platform to create novel, disease-modifying therapies for patients with few or no treatment options.

What specific diseases is Retrotope inc. currently targeting in their pipeline?

The company's pipeline includes RT001, which targets Infantile Neuroaxonal Dystrophy (INAD), Friedreich's Ataxia (FA), Amyotrophic Lateral Sclerosis (ALS), and Progressive Supranuclear Palsy (PSP). RT011 is being developed for Dry Age-Related Macular Degeneration (Dry AMD) and geographic atrophy (GA). Other future targets include Huntington's disease, Spinocerebellar ataxia, and Multiple system atropy.

What do multiple reviewers consistently praise about Retrotope inc.?

Reviewers frequently highlight the team's high proficiency, dedication, and ability to deliver top-quality solutions that exceed expectations. Many customers note the team's responsiveness, professionalism, and deep understanding of business requirements, often describing the experience as amazing and highly recommendable.

What specific clinical trial milestones has Retrotope inc. announced recently?

In June 2021, Retrotope announced the initiation of a Phase 2 study for RT001 in patients with Progressive Supranuclear Palsy (PSP). They also completed enrollment in Phase 2 studies for ALS and PSP, with some studies exceeding their enrollment targets in less than six weeks, leading to expectations of data availability by the end of 2021.

What is the address of Retrotope inc.'s headquarters?

Retrotope inc. is located at 4300 El Camino Real, Suite 201, Los Altos, CA 94022. This location serves as their primary office for operations and communications.

What is the mission statement of Retrotope inc.?

The company's mission is to pioneer the development of first-in-class therapies for devastating degenerative diseases, ranging from orphan neurodegenerative indications to large market conditions. They aim to combat oxidative stress and cellular degeneration arising from lipid peroxidation through their proprietary drug discovery platform technology.

Which key personnel are listed on Retrotope inc.'s management team?

The management team includes Anil Kumar, MBA, as President; Mikhail S. Shchepinov, PhD, as Founder and CSO; Peter G. Milner, MD, as CMO; Vidhya Gopalakrishnan, PhD, as CDO; and Karsten Schmidt, PhD, as Senior VP of Ophthalmology. George Garibaldi, MD, serves as a Director.

What specific scientific mechanism does Retrotope inc. focus on for their therapeutics?

The company focuses on reinforcing the molecules of life by targeting lipid peroxidation (LPO), which drives oxidative stress and cellular degeneration. By down-regulating LPO, they aim to protect against cellular degeneration in various degenerative diseases.

How many research programs and collaborations does Retrotope inc. claim to have?

The company states they have over 10 research programs, 100+ collaborators, and partnerships with over 25 research institutions. They have also dosed over 100 patients and utilize over 1000 patient/month of drug usage.

What specific news or events were highlighted in Retrotope inc.'s press releases?

Notable events include the announcement of positive results from RT011 studies in animal models of retinal degeneration featured at the 2nd Annual Dry AMD Therapeutic Development Summit in October 2021. Additionally, they reported data from a Phase 2/3 clinical trial of RT001 and concurrent natural history study in patients with INAD.

What is the scope of Retrotope inc.'s pipeline in terms of discovery phases?

The pipeline spans from Discovery/Preclinical phases through Phase I, Phase II, and Phase III trials. Specific compounds like RT001 and RT011 are in various stages, with some moving into late-stage clinical trials for orphan neurodegenerative diseases.

What are the key features of the patient resources section on Retrotope inc.'s website?

The patient resources section includes an Expanded Access Policy, Clinical Trials information, and Additional Resources. These sections aim to provide comprehensive support and information for patients and providers interested in their therapeutic candidates.

How can I contact Retrotope inc.?

You can reach Retrotope inc. by phone at 16504370700 or by e-mail at info@retrotope.com.

How is Retrotope inc. rated on Trustburn?

On Trustburn, Retrotope inc. has a rating of 3.9 out of 5 based on 11 reviews.

Is Retrotope inc. on social media?

Retrotope inc. has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

Terry Meyers
Reviews 1

I recently had the pleasure of working with Retrotope inc. and I must say it was a great experience. The team at Retrotope is highly professional and knowledgeable. They were able to provide excellent solutions to our business needs. I would highly recommend Retrotope inc. to anyone looking for a reliable and innovative partner.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Retrotope inc.

Retrotope is developing a pipeline of proprietary therapeutics designed to treat degenerative disease by down-regulating LPO in order to protect against cellular degeneration.

Retrotope Inc. - Revolutionizing the Treatment of Degenerative Diseases

Retrotope Inc. is a biopharmaceutical company that is dedicated to developing innovative therapeutics for the treatment of degenerative diseases. The company's mission is to provide hope and relief to patients suffering from debilitating conditions by developing novel drugs that target the underlying causes of these diseases.

Degenerative diseases are a group of disorders that affect millions of people worldwide, causing progressive deterioration and loss of function in various organs and tissues. These conditions include Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), multiple sclerosis, and many others.

The current treatments for degenerative diseases are limited in their effectiveness and often come with significant side effects. Retrotope aims to change this by developing a pipeline of proprietary therapeutics designed to treat degenerative disease by down-regulating LPO (lipid peroxidation) in order to protect against cellular degeneration.

Lipid peroxidation is a process that occurs when free radicals attack lipids (fats) in cell membranes, leading to oxidative damage and cell death. This process plays a critical role in the development and progression of many degenerative diseases.

Retrotope has developed a unique approach to treating these conditions by targeting LPO directly. The company's lead drug candidate, RT001, is an orally administered small molecule that has been shown to be effective at reducing LPO levels in preclinical studies.

RT001 works by replacing vulnerable fatty acids with stable isotopes that resist oxidation by free radicals. This stabilizes cell membranes and protects them from damage caused by lipid peroxidation.

In addition to RT001, Retrotope has several other drug candidates in its pipeline targeting different aspects of lipid metabolism and oxidative stress pathways involved in degenerative diseases.

The company has also developed proprietary biomarkers for measuring LPO levels in patients' blood samples, which will be used to monitor the effectiveness of its drugs in clinical trials.

Retrotope's innovative approach to treating degenerative diseases has attracted significant attention from investors and the scientific community. The company has raised over $50 million in funding to date and has established collaborations with leading academic institutions and pharmaceutical companies.

The potential market for Retrotope's therapeutics is enormous, with millions of patients worldwide suffering from degenerative diseases that currently have no cure. The company's drugs have the potential to transform the lives of these patients by slowing or even reversing disease progression, improving quality of life, and reducing healthcare costs.

In conclusion, Retrotope Inc. is a biopharmaceutical company that is at the forefront of developing innovative therapeutics for degenerative diseases. Its unique approach targeting LPO holds great promise for treating a wide range of conditions that currently have no effective treatments. With its strong pipeline, proprietary biomarkers, and experienced team, Retrotope is poised to make a significant impact on the field of regenerative medicine in the years ahead.

Address
4300 el camino real
Categories
Pharmaceuticals